Enzymotec (NASDAQ:ENZY) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, January 6th.
Other equities research analysts have also issued research reports about the company. Jefferies Group reissued a “hold” rating and issued a $11.50 target price on shares of Enzymotec in a research note on Thursday, October 19th. Zacks Investment Research raised Enzymotec from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 17th. Finally, Wells Fargo & Co boosted their price target on Enzymotec from $9.50 to $12.00 and gave the company a “market perform” rating in a report on Monday, October 30th. One research analyst has rated the stock with a sell rating and four have given a hold rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $11.75.
Enzymotec (NASDAQ ENZY) opened at $11.85 on Friday. Enzymotec has a 52-week low of $6.30 and a 52-week high of $12.35. The company has a market capitalization of $277.62, a PE ratio of -43.89, a P/E/G ratio of 3.19 and a beta of 1.22.
Enzymotec (NASDAQ:ENZY) last posted its earnings results on Wednesday, November 15th. The biotechnology company reported $0.04 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.03). Enzymotec had a return on equity of 1.24% and a net margin of 2.32%. analysts forecast that Enzymotec will post 0.05 EPS for the current fiscal year.
Several hedge funds have recently bought and sold shares of the business. State Street Corp grew its holdings in shares of Enzymotec by 1.8% during the 2nd quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock worth $169,000 after acquiring an additional 380 shares during the period. JPMorgan Chase & Co. purchased a new position in shares of Enzymotec during the 3rd quarter worth approximately $107,000. SG Americas Securities LLC purchased a new position in shares of Enzymotec during the 4th quarter worth approximately $116,000. Osborn Williams & Donohoe LLC purchased a new stake in shares of Enzymotec in the 3rd quarter worth approximately $137,000. Finally, Janus Henderson Group PLC purchased a new stake in shares of Enzymotec in the 2nd quarter worth approximately $2,350,000. Hedge funds and other institutional investors own 15.73% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/29/enzymotec-enzy-lowered-to-sell-at-bidaskclub.html.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec and related companies with MarketBeat.com's FREE daily email newsletter.